

# New Venturetec

## NET ASSET VALUE - October 31, 2017

Shares issued private	4'500'000	Price: USD 23.83	USD 107'250'000
Shares issued IPO	500'000	Price: CHF 33.00 (ex.rate 1.47)	USD 11'250'000
	<b>5,000,000</b>		<b>USD 118'500'000</b>

Convertible Bond 2018: See details below

<b>Total paid in capital</b>	<b>USD</b>	<b>118'500'000.00</b>
------------------------------	------------	-----------------------

Realized gain* (since inception to date)	USD	74'994'626.11
Realized loss* (since inception to date)	USD	109'585'211.82

\*inclusive reinvestments

### Investment appreciation of current portfolio companies

Unrealized gain	USD	987'499.11
Unrealized loss	USD	-3'264'427.93
<b>Total appreciation</b>	USD	<b>-2'276'928.82</b>

### NAV

Cost of investments	USD	29'649'433.82
Appreciation of investments	USD	-2'276'928.82
Estimated value of investments	USD	<b>27'372'505.00</b>
Convertible bond 2018	USD	-15'566'732.42
Loan	USD	-6'697'259.24
Bank Loan	USD	0.00
Accrued expenses	USD	0.00
Accounts receivables	USD	53'962.08
Cash at bank	USD	1'951'990.57
<b>Estimated value</b>	USD	<b>7'114'465.99</b>
<b>NAV per share USD</b>		<b>1.42</b>
<b>NAV per share CHF</b>		<b>1.42</b>

Exchange rate USD/CHF	0.9970
<b>Closing Market Price October 31, 2017</b>	<b>CHF 1.91</b>

## New Venturetec NAV - October 31, 2017

INDUSTRY/ COMPANY	AMOUNT USD	% CAPITAL	SECURITIES	PRICE COST	PRICE REPORTED	UNREALIZED GAIN (LOSS)	TOTAL EST. VALUE	% NAV
1. Osiris Therapeutics, Inc.	23'780'932.93	80.2	4'103'301 Common Shares	5.80	5.00	-3'264'427.93	20'516'505.00	69.9
2. Myriad Genetics	5'868'500.89	19.8	200'000 Shares	29.34	34.28	987'499.11	6'856'000.00	23.4
<b>TOTAL</b>	<b>29'649'433.82</b>	<b>100.0</b>				<b>-2'276'928.82</b>	<b>27'372'505.00</b>	<b>93.3</b>